Linerixibat Patent Expiration

Linerixibat was first introduced by Glaxosmithkline Llc in its drug Lynavoy on Mar 17, 2026.


Linerixibat Patents

Given below is the list of patents protecting Linerixibat, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lynavoy US9040518 Chemical Compounds Sep 06, 2031 Glaxosmithkline



Linerixibat's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Linerixibat Generic API Manufacturers

Given below is the list of companies who have filed for Linerixibat generic, along with the locations of their manufacturing plants worldwide.